Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 71.4%High 0 · 0%

Methylxanthine vs placebo or control

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with apnea

The review found no eligible studies for this question.

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methylxanthine vs placebo or control

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants prior to extubation

The review found no eligible studies for this question.

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methylxanthine vs placebo or control

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine probably leads to lower major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.85 [0.76, 0.96]
1 study · 1869 participants
Moderate

Methylxanthine vs placebo or control

Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.87 [0.78, 0.97]
1 study · 1869 participants
Moderate

Methylxanthine vs placebo or control

Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk for apnea

Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 1 [0.8, 1.24]
1 study · 423 participants
Moderate

Methylxanthine vs placebo or control

Death or major neurodevelopmental disability at 18 to 24 months · preterm infants with apnea

Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.85 [0.71, 1.01]
1 study · 767 participants
Moderate

Methylxanthine vs placebo or control

Death or major neurodevelopmental disability at 18 to 24 months · preterm infants prior to extubation

Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.85 [0.73, 0.99]
1 study · 676 participants
Moderate